13338-63-1Relevant articles and documents
-
Cason,J.,Lynch,D.M.
, p. 1883 - 1887 (1966)
-
Combretastatin A4 analogue containing cyanoethylene joining chain and application in preparing antitumor drugs
-
Paragraph 0044; 0054; 0055; 0056, (2019/03/15)
The invention a Combretastatin A4 analogue containing a cyanoethylene joining chain and an application in preparing antitumor drugs, which relates to the field of a medicinal compound. A structural formula (I-IV) is shown as the specification, an anticancer candidate compound which has strong inhibitory activity against cancer cells and is not toxic to normal cells is currently lacked, for the reason, the method prepares 19 I-IV series compounds, and the para and meta positions of the B ring (benzene ring) introduce various alkyl groups, alkoxy groups or amino substituents or replace the B ring (benzene ring) with various heterocyclic rings. In the I-series compound, when the para position of the B ring (benzene ring) is substituted with an ethyl group, an isopropyl group, a dimethylaminogroup or a diethylamino group, the proliferation resistance of the cancer cells is very strong, and toxicity is weak for the L-02 normal cells, a selective anticancer activity coefficient (an IC50 value ratio of L-02 normal cells to cancer cells) can even exceed 10,000, and the four compounds have the potential to be developed into safe and highly effective anticancer drugs.
Synthesis and characterisation of (Z)-styrylbenzene derivatives as potential selective anticancer agents
Xin, Ya-Bing,Li, Jia-Jun,Zhang, Hong-Jian,Ma, Jun,Liu, Xin,Gong, Guo-Hua,Tian, Yu-Shun
, p. 1554 - 1564 (2018/10/02)
To identify anticancer agents with high potency and low toxicity, a series of (Z)-styrylbenzene derivatives were synthesised and evaluated for anticancer activities using a panel of nine cancer cell lines and two noncancerous cell lines. Most derivatives exhibited significant anti-proliferative activities against five cancer cell lines, including MGC-803 and BEL-7402. (Z)-3-(p-Tolyl)-2-(3,4,5-trimethoxyphenyl)acrylonitrile (6h) showed a strong inhibitory effect on MGC-803 cells (IC50 50 50 value of 6h in L-02 cells was 10,000-fold higher than in MGC-803 cells. Compound 6h inhibited proliferation of BEL-7402 cells by arresting at the G2/M phase through up-regulation of cyclin B1 expression, down-regulation of cyclin A and D1 expression, and induction of apoptosis. In addition, 6h inhibited the migration of BEL-7402 cells and the formation of cell colonies.
TYD1608 with selective anti-cancer activity as well as preparation and application thereof
-
Paragraph 0012; 0013; 0025-0027, (2018/11/22)
The invention provides cyan-containing TYD1608, i.e., (Z)-3-(p-methyl phenyl)-2-(3,4,5-trimethoxyphenyl) acrylonitrile as well as preparation and application thereof, and relates to the field of medicinal compounds with the structure shown in the description. Various anti-cancer medicine in the prior art have the killing capability on cancer cells and also have great toxicity on normal cells; thetreatment of cancer patients is seriously influenced, so that the invention of the medicine with the selective anti-cancer activity on the normal cells is very important. The TYD1608 is synthesized; the compound shows strong proliferation inhibition capability on six kinds of human face cancer cells; in addition, the toxicity on the L-02 normal human liver cells is weak. The IC50 value on the MGC-803 gastric cancer cells is smaller than 0.01 mu M, is better than the clinic common use anti-cancer medicine of taxol; good selective anti-cancer activity is realized. Mechanism study shows that theproliferation inhibition activity of the TYD1608 on BEL-7402 cancer cells is the result of inhibiting the G2/M period in the cell period, inducting early stage and later stage apoptosis, blocking cellmigration, inhibiting cell period relevant protein cyclin A1 and cyclin D1.